// App-Quantinova.ai

: Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD

Researchers

Presenter

  • Tara Rheault

Principal Investigators

  • Joseph A Boscia

  • Brian Maurer

  • Kathleen Rickard

Medical Centers

  • Verona Pharma, London, United Kingdom,

  • VitaLink Research, Union, SC, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Salbutamol

  • RPL554

Outcome

  • N/A

Study Design

  • Placebo Control

  • Parallel Group

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Verona Pharma

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved